Pharmacology Research and Perspectives This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Pharmacist intervention to improve adherence to medication among heart failure patients at North East Ethiopia hospital
AbstractHeart failure (HF) is a major and growing medical problem and its management is still challenging due to the coexistence of complications, co-morbidity, and medication non-adherence. HF patients who are adherent to their medication have fewer HF exacerbations, improved survival, and lower healthcare expenditure. Adherence to HF medication plays a pivotal role in attaining maximal therapeutic outcomes. The aim was to assess the medication adherence of heart failure patients at Debre Berhan Comprehensive Specialized Hospital (DBCSH). A pre-post interventional study was undertaken from July 1, 2022, to December 31, 20...
Source: Pharmacology Research and Perspectives - May 1, 2024 Category: Drugs & Pharmacology Authors: Abate Wondesen Tsige, Tsegaye Ababiya Kotiso, Kassahun Dires Ayenew, Siraye Genzeb Ayele Tags: ORIGINAL ARTICLE Source Type: research

Prediction of cell cycle distribution after drug exposure by high content imaging analysis using low ‐toxic DNA staining dye
In this study, we developed the cell cycle prediction model using high-content imaging data of recipient cells after drug exposure and DNA-staining with a low-toxic DNA dye, SiR-DNA. For this purpose, we exploited HeLa and MCF7 cells introduced with a fluorescent ubiquitination-based cell cycle indicator (Fucci). Fucci-expressing cancer cells were subjected to high-content imaging analysis using OperettaCLS after 36-h exposure to anticancer drugs; the nuclei were segmented, and the morphological and intensity properties of each nucleus characterized by SiR-DNA staining were calculated using imaging analysis software, Harmo...
Source: Pharmacology Research and Perspectives - April 30, 2024 Category: Drugs & Pharmacology Authors: Kazuma Takeuchi, Yumiko Nishimura, Takayoshi Matsubara, Sho Isoyama, Asuka Suzuki, Masaaki Matsuura, Shingo Dan Tags: SHORT REPORT Source Type: research

Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations
Linkage disequilibrium for SNPs associated with metabolizerNAT2. (A) mestizo population (B) native population. AbstractIn Peru, 29  292 people were diagnosed with tuberculosis in 2022. Although tuberculosis treatments are effective, 3.4%–13% are associated with significant adverse drug reactions, with drug-induced liver injury (DILI) considered the most predominant. Among the first-line antituberculosis drugs, isoniazid is the main drug responsible for the appearance of DILI. In liver, isoniazid (INH) is metabolized by N-acetyltransferase-2 (NAT2) and cytochrome P450 2E1 (CYP2E1). Limited information exists on genetic ...
Source: Pharmacology Research and Perspectives - April 27, 2024 Category: Drugs & Pharmacology Authors: Luis Jaramillo ‐Valverde, Kelly S. Levano, David D. Tarazona, Silvia Capristano, Cesar Sanchez, Julio A. Poterico, Eduardo Tarazona‐Santos, Heinner Guio Tags: ORIGINAL ARTICLE Source Type: research

Clinical pharmacology and tolerability of REC ‐994, a redox‐cycling nitroxide compound, in randomized phase 1 dose‐finding studies
Cerebral cavernous malformation (CCM) pathogenesis involves elevated reactive oxygen species (ROS) levels. REC-994 restores ROS balance, and in double-blind, placebo-controlled, trials in healthy volunteers, had low potential for off-target adverse effects and pharmacokinetics suitable for phase 2 development. AbstractCerebral cavernous malformation (CCM) has variable clinical symptoms, including potentially fatal hemorrhagic stroke. Treatment options are very limited, presenting a large unmet need. REC-994 (also known as tempol), identified as a potential treatment through an unbiased drug discovery platform, is hypothesi...
Source: Pharmacology Research and Perspectives - April 25, 2024 Category: Drugs & Pharmacology Authors: Ron Alfa, Timothy Considine, Shafique Virani, Matt Pfeiffer, Anthony Donato, Daniel Dickerson, Diana Shuster, Joel Ellis, Kristen Rushton, Helen Wei, Christopher Gibson Tags: ORIGINAL ARTICLE Source Type: research

Induction of hepatic CYP3A4 expression by cholesterol and cholic acid: Alterations of gene expression, microsomal activity, and pharmacokinetics
In conclusion, our study suggested that hepatic CYP3A4 expression and activity are influenced by the combination of cholesterol and cholic acid in  vivo. (Source: Pharmacology Research and Perspectives)
Source: Pharmacology Research and Perspectives - April 22, 2024 Category: Drugs & Pharmacology Authors: Genki Minegishi, Yuka Kobayashi, Mayu Fujikura, Ayane Sano, Yasuhiro Kazuki, Kaoru Kobayashi Tags: ORIGINAL ARTICLE Source Type: research

Impact of pharmaceutical care for asthma patients on health ‐related outcomes: An umbrella review
Preferred reporting items for systematic reviews and meta-analyses literature search and study selection flowchart. AbstractRecent systematic reviews suggest that pharmacists' interventions in asthma patients have a positive impact on health-related outcomes. Nevertheless, the association is not well established, and the role of clinical pharmacists is poorly represented. The aim of this overview of systematic reviews is to identify published systematic reviews assessing the impact of pharmacists' interventions on health-related outcomes measured in asthma patients. PubMed, Embase, Scopus, and Cochrane Library were searche...
Source: Pharmacology Research and Perspectives - April 22, 2024 Category: Drugs & Pharmacology Authors: Olalla Montero  Pérez, Fernando Salazar González, Ernesto Sánchez Gómez, Concepción Pérez Guerrero Tags: REVIEW Source Type: research

Coadministration of fluconazole to boost subtherapeutic sirolimus concentrations: A case report
During a toxoplasmosis infection in a patient with hematopoietic stem cell transplantation, sirolimus concentrations fell into the subtherapeutic range and therapeutic concentrations could not be achieved despite dose escalation. This was finally achieved by CYP3A4 inhibition with fluconazole (pharmacoenhancement) and twice-daily (off-label) administration of sirolimus. AbstractIndividual sirolimus whole blood concentrations are highly variable, critically influenced by the concomitant use of cytochrome P450 (CYP) 3A inducers or inhibitors, and also modulated by food. Therapeutic drug monitoring is therefore recommended, e...
Source: Pharmacology Research and Perspectives - April 19, 2024 Category: Drugs & Pharmacology Authors: Camilo Scherkl, Andreas D. Meid, Sven E. Cuntz, Laura Classen, Johanna Weiss, David Czock, Walter E. Haefeli Tags: SHORT REPORT Source Type: research

Issue Information
(Source: Pharmacology Research and Perspectives)
Source: Pharmacology Research and Perspectives - April 18, 2024 Category: Drugs & Pharmacology Tags: ISSUE INFORMATION Source Type: research

Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC ‐HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel
Extracted ion chromatograms of drug-related material from pooled plasma after administration of LCIG and foslevodopa/foscarbidopa to healthy human participants AbstractAnalysis was conducted to compare levodopa/carbidopa pharmacokinetics and drug-related material in plasma of healthy participants after receiving a continuous infusion of Levodopa/Carbidopa Intestinal Gel (LCIG) to a continuous subcutaneous infusion of foslevodopa/foscarbidopa. Study samples were from a randomized, open-label, 2-period crossover study in 20 healthy participants. Participants received either 24-h foslevodopa/foscarbidopa SC infusion to the ab...
Source: Pharmacology Research and Perspectives - April 11, 2024 Category: Drugs & Pharmacology Authors: John P. Savaryn, Richard L. Smith, Matthew Rosebraugh, Melina Neenan, Richard Burton, Kennan Marsh, David Wagner Tags: ORIGINAL ARTICLE Source Type: research

Absorption and pharmacokinetics of bupivacaine after bilateral topical administration in tonsillar fossae for posttonsillectomy pain relief
In conclusion, this study shows that applying 4 mL of bupivacaine 5 mg/mL by a swab in the tons illar fossae posttonsillectomy yields very low plasma concentrations, suggesting its safe application without any risk of systemic toxic effects. (Source: Pharmacology Research and Perspectives)
Source: Pharmacology Research and Perspectives - April 10, 2024 Category: Drugs & Pharmacology Authors: Kristin Sandal Berg, Ellisiv Seines, Peter G ál, Lise Løberg‐Emanuelsen, Audun Stubhaug, Erik Waage Nielsen, Olav Spigset Tags: ORIGINAL ARTICLE Source Type: research

Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin ‐converting enzyme 2
We found that UDCA-fed hamsters effectively inhibited viral transmission from Omicron variant-infected hamsters and verified UDCA-derived downregulation of ACE2 expression in respiratory organs. As an FXR antagonist, UDCA may protect against SARS-CoV-2 Omicron variant. AbstractThe SARS-CoV-2 caused COVID-19 pandemic has posed a global health hazard. While some vaccines have been developed, protection against viral infection is not perfect because of the urgent approval process and the emergence of mutant SARS-CoV-2 variants. Here, we employed UDCA as an FXR antagonist to regulate ACE2 expression, which is one of the key pa...
Source: Pharmacology Research and Perspectives - April 5, 2024 Category: Drugs & Pharmacology Authors: Kyungmin Lee, Yujeong Na, Minjin Kim, Dongjin Lee, Jongseo Choi, Gwanyoung Kim, Min ‐Soo Kim Tags: ORIGINAL ARTICLE Source Type: research

Lanthanum hydroxide protects kidney through gut microbiota in a rat model of chronic kidney disease
This study underscores the significance of lanthanum hydroxide in kidney protection, attributing its benefits to the modulation of gut microbiota in a rat model of CKD. (Source: Pharmacology Research and Perspectives)
Source: Pharmacology Research and Perspectives - April 2, 2024 Category: Drugs & Pharmacology Authors: Yuan Gao, Shengnan Wang, Lijun Sun, Bing Li, Hong Liu, Ren Bu, Changhai Su, Min Guo, Yang Liu, Lulu Zhao, Chao Gu, Xiaojia Li, Xiaorong Yuan, Qiwen Wang, Gang Li Tags: ORIGINAL ARTICLE Source Type: research

Evaluation of OCT2 ‐mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia
Plasma and urine pharmacokinetic parameters of metformin along and in combination with ulotaront. AbstractUlotaront (SEP-363856) is a TAAR1 agonist, with 5-HT1A agonist activity, currently in clinical development for the treatment of schizophrenia. In  vitro studies indicate ulotaront is an OCT2-specific inhibitor with IC50 of 1.27  μM. The primary objective of this study is to determine if a single dose of ulotaront affects the PK of metformin, an index substrate of OCT2, in subjects with schizophrenia. In a randomized, single-blind, 2-period crossover study, 25 adults with schizophrenia received a single dose of metf...
Source: Pharmacology Research and Perspectives - March 26, 2024 Category: Drugs & Pharmacology Authors: Guangqing Xiao, Hironobu Tsukada, Yu ‐Luan Chen, Lei Shi, Seth C. Hopkins, Gerald R. Galluppi Tags: ORIGINAL ARTICLE Source Type: research